ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non‐small cell lung cancer

Bo Mi Ku(Samsung Medical Center), Myung‐Ju Ahn(Samsung Medical Center)

Investigational New Drugs

January 1, 2022

10.1007/s10637-021-01121-6

Cited by 8

Related Papers

MDSC subtypes and CD39 expression on CD8 <sup>+</sup> T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC

|European Journal of Immunology|2020|90

Caffeine Inhibits Cell Proliferation and Regulates PKA/GSK3β Pathways in U87MG Human Glioma Cells

|Molecules and Cells|2011|76

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer

|Investigational New Drugs|2019|50

CpG oligodeoxynucleotides induce IL-8 expression in CD34+ cells via mitogen-activated protein kinase-dependent and NF-κB-independent pathways

|International Immunology|2005|40

Mutational status of <i>TP53</i> defines the efficacy of Wee1 inhibitor AZD1775 in <i>KRAS</i>-mutant non-small cell lung cancer

|Oncotarget|2017|40